ARYX OTC
ARYx Therapeutics, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: +25.0%
5Y: -72.2%
$0.00
Last traded 2026-08-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
-100.0% ▼
Operating Income
-$31M
-2.7% ▼
Net Income
-$33M
-6.2% ▼
EPS (Diluted)
$-1.21
+26.7% ▲
EBITDA
-$30M
-2.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2005 | FY2006 | FY2007 | FY2008 | FY2009 |
|---|---|---|---|---|---|
| Revenue | $0 | $5M | $4M | $20M | $0 |
| YoY Growth | +0.0% | +0.0% | -12.3% | +374.4% | -100.0% |
| Cost of Revenue | $0 | $2M | $262K | $232K | $0 |
| Gross Profit | $0 | $3M | $4M | $19M | $0 |
| Gross Margin | — | 55.3% | 93.7% | 98.8% | — |
| R&D Expenses | $22M | $24M | $25M | $40M | $21M |
| SG&A Expenses | $6M | $7M | $8M | $10M | $10M |
| Operating Expenses | $28M | $31M | $33M | $50M | $31M |
| Operating Income | -$28M | -$28M | -$29M | -$30M | -$31M |
| Operating Margin | — | -596.9% | -692.6% | -154.2% | — |
| Interest Expense | $671K | $1M | $1M | $2M | $2M |
| Income Before Tax | $0 | $0 | $0 | $0 | $0 |
| Tax Expense | -$205K | -$960K | -$1M | $801K | $849K |
| Net Income | -$28M | -$27M | -$28M | -$31M | -$33M |
| Net Margin | — | -576.7% | -662.8% | -158.3% | — |
| EPS (Diluted) | $-30.73 | $-26.84 | $-2.93 | $-1.65 | $-1.21 |
| EBITDA | -$27M | -$27M | -$28M | -$29M | -$30M |
| Shares Outstanding | 910000 | 1M | 9M | 19M | 27M |